FDA Needs External Board To Boost Industry Input – von Eschenbach
This article was originally published in The Tan Sheet
Executive Summary
At the Forbes health care summit, thought leaders pitched ways to improve FDA and the processes of making medical innovations available. FDA Commissioner Hamburg cited the agency’s openness to biomarkers, innovative clinical trial designs and mandatory recall authority.
You may also be interested in...
Patient Community Is FDA’s “Guiding Light” On Acceptable Drug Risks
CDER’s Janet Woodcock says the community has the agency’s ear when it advocates new developments; cites need for an “adult conversation” in assessing when drugs should be made available to patients.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.